Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour ...

Real-world data (RWD) is an asset for vaccine research, safety monitoring, and education efforts, and is essential toward ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

Chugai has signed a definitive stock agreement to purchase Japan-based Renalys Pharma, augmenting its kidney disease ...

Novartis has signed an agreement for the acquisition of all the outstanding shares of US-based Avidity Biosciences.

Zavodnick told Pharmaceutical Technology that Excellergy plans to initiate an ex-US Phase I study of its lead ECRI candidate, a monoclonal antibody, in Q1 2026, with the goal of being ready for Phase ...

The MHRA's raid follows an uptick in the trade of illegal GLP-1RA drugs used for obesity and type 2 diabetes amid shortages ...

Lilly and Inctye will be seeking a label update for the JAK inhibitor for its use in paediatric patients with alopecia areata ...

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

GSK has received US Food and Drug Administration (FDA) approval for Blenrep to be used along with BVd for multiple myeloma.

Immunotherapy drugs continue to gain momentum across a growing range of disease areas with blockbusters such as Merck’s ...